Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin

Tatsuya Fujino, Makoto Nakamuta, Yoko Aoyagi, Motoyuki Kohjima, Takeaki Satoh, Mika Fukuda, Hiromi Ishibashi, Hiroshi Yatsuhashi, Munechika Enjoji

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: We aimed to assess differences in early viral dynamics following treatment with either peg-IFNα2a or peg-IFNα2b in combination with ribavirin in patients with chronic genotype 1b HCV infection. Material/Methods: Sixty-one patients in the peg-IFNα2a + ribavirin treatment (group α2a) and 88 patients in the peg- IFNα2b + ribavirin treatment (group α2b) were retrospectively analyzed. The early dynamics of HCV RNA over 12 weeks were evaluated. Sustained virological response (SVR) was defined as undetectable HCV RNA at week 24 after end of therapy. First- (day 0-1) and second-phase (day 1-28) viral decline rates were calculated in accordance with theoretical formulae. Results: Baseline HCV RNA concentrations were almost similar between the 2 groups. In group α2a, viral decline was significantly greater than in group α2b at weeks 4, 8, and 12. In group α2a, viral decline was significantly greater in SVR patients than in non-SVR patients at week 2, whereas significantly greater viral decline in SVR patients was found during weeks 1-12 in group α2b. The first-phase viral decline rate was significantly larger in group α2a than in group α2b (1.31±0.84 vs. 0.70±0.97 log IU/mL/day; p<0.0001). Within SVR patients, first-phase viral decline rate was significantly larger in group α2a compared with group α2b (1.45±0.85 vs. 0.78±1.0 log IU/mL/day; p<0.0001). Second-phase viral decline rate was comparable between the groups. Conclusions: Peg-IFNα2a showed earlier viral decline than peg-IFNα2b and the difference was obvious, especially in the first-phase viral decline.

Original languageEnglish
Pages (from-to)CR687-CR691
JournalMedical Science Monitor
Volume17
Issue number12
DOIs
Publication statusPublished - Jan 1 2011
Externally publishedYes

Fingerprint

Ribavirin
Viremia
Chronic Hepatitis C
Genotype
RNA
Therapeutics
Infection

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C : Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin. / Fujino, Tatsuya; Nakamuta, Makoto; Aoyagi, Yoko; Kohjima, Motoyuki; Satoh, Takeaki; Fukuda, Mika; Ishibashi, Hiromi; Yatsuhashi, Hiroshi; Enjoji, Munechika.

In: Medical Science Monitor, Vol. 17, No. 12, 01.01.2011, p. CR687-CR691.

Research output: Contribution to journalArticle

Fujino, Tatsuya ; Nakamuta, Makoto ; Aoyagi, Yoko ; Kohjima, Motoyuki ; Satoh, Takeaki ; Fukuda, Mika ; Ishibashi, Hiromi ; Yatsuhashi, Hiroshi ; Enjoji, Munechika. / Early dynamics of viremia in patients with genotype 1b chronic hepatitis C : Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin. In: Medical Science Monitor. 2011 ; Vol. 17, No. 12. pp. CR687-CR691.
@article{86dc2132ff3946d19fa6266532c86123,
title = "Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin",
abstract = "Background: We aimed to assess differences in early viral dynamics following treatment with either peg-IFNα2a or peg-IFNα2b in combination with ribavirin in patients with chronic genotype 1b HCV infection. Material/Methods: Sixty-one patients in the peg-IFNα2a + ribavirin treatment (group α2a) and 88 patients in the peg- IFNα2b + ribavirin treatment (group α2b) were retrospectively analyzed. The early dynamics of HCV RNA over 12 weeks were evaluated. Sustained virological response (SVR) was defined as undetectable HCV RNA at week 24 after end of therapy. First- (day 0-1) and second-phase (day 1-28) viral decline rates were calculated in accordance with theoretical formulae. Results: Baseline HCV RNA concentrations were almost similar between the 2 groups. In group α2a, viral decline was significantly greater than in group α2b at weeks 4, 8, and 12. In group α2a, viral decline was significantly greater in SVR patients than in non-SVR patients at week 2, whereas significantly greater viral decline in SVR patients was found during weeks 1-12 in group α2b. The first-phase viral decline rate was significantly larger in group α2a than in group α2b (1.31±0.84 vs. 0.70±0.97 log IU/mL/day; p<0.0001). Within SVR patients, first-phase viral decline rate was significantly larger in group α2a compared with group α2b (1.45±0.85 vs. 0.78±1.0 log IU/mL/day; p<0.0001). Second-phase viral decline rate was comparable between the groups. Conclusions: Peg-IFNα2a showed earlier viral decline than peg-IFNα2b and the difference was obvious, especially in the first-phase viral decline.",
author = "Tatsuya Fujino and Makoto Nakamuta and Yoko Aoyagi and Motoyuki Kohjima and Takeaki Satoh and Mika Fukuda and Hiromi Ishibashi and Hiroshi Yatsuhashi and Munechika Enjoji",
year = "2011",
month = "1",
day = "1",
doi = "10.12659/MSM.882127",
language = "English",
volume = "17",
pages = "CR687--CR691",
journal = "Medical Science Monitor",
issn = "1234-1010",
publisher = "International Scientific Literature Inc.",
number = "12",

}

TY - JOUR

T1 - Early dynamics of viremia in patients with genotype 1b chronic hepatitis C

T2 - Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin

AU - Fujino, Tatsuya

AU - Nakamuta, Makoto

AU - Aoyagi, Yoko

AU - Kohjima, Motoyuki

AU - Satoh, Takeaki

AU - Fukuda, Mika

AU - Ishibashi, Hiromi

AU - Yatsuhashi, Hiroshi

AU - Enjoji, Munechika

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Background: We aimed to assess differences in early viral dynamics following treatment with either peg-IFNα2a or peg-IFNα2b in combination with ribavirin in patients with chronic genotype 1b HCV infection. Material/Methods: Sixty-one patients in the peg-IFNα2a + ribavirin treatment (group α2a) and 88 patients in the peg- IFNα2b + ribavirin treatment (group α2b) were retrospectively analyzed. The early dynamics of HCV RNA over 12 weeks were evaluated. Sustained virological response (SVR) was defined as undetectable HCV RNA at week 24 after end of therapy. First- (day 0-1) and second-phase (day 1-28) viral decline rates were calculated in accordance with theoretical formulae. Results: Baseline HCV RNA concentrations were almost similar between the 2 groups. In group α2a, viral decline was significantly greater than in group α2b at weeks 4, 8, and 12. In group α2a, viral decline was significantly greater in SVR patients than in non-SVR patients at week 2, whereas significantly greater viral decline in SVR patients was found during weeks 1-12 in group α2b. The first-phase viral decline rate was significantly larger in group α2a than in group α2b (1.31±0.84 vs. 0.70±0.97 log IU/mL/day; p<0.0001). Within SVR patients, first-phase viral decline rate was significantly larger in group α2a compared with group α2b (1.45±0.85 vs. 0.78±1.0 log IU/mL/day; p<0.0001). Second-phase viral decline rate was comparable between the groups. Conclusions: Peg-IFNα2a showed earlier viral decline than peg-IFNα2b and the difference was obvious, especially in the first-phase viral decline.

AB - Background: We aimed to assess differences in early viral dynamics following treatment with either peg-IFNα2a or peg-IFNα2b in combination with ribavirin in patients with chronic genotype 1b HCV infection. Material/Methods: Sixty-one patients in the peg-IFNα2a + ribavirin treatment (group α2a) and 88 patients in the peg- IFNα2b + ribavirin treatment (group α2b) were retrospectively analyzed. The early dynamics of HCV RNA over 12 weeks were evaluated. Sustained virological response (SVR) was defined as undetectable HCV RNA at week 24 after end of therapy. First- (day 0-1) and second-phase (day 1-28) viral decline rates were calculated in accordance with theoretical formulae. Results: Baseline HCV RNA concentrations were almost similar between the 2 groups. In group α2a, viral decline was significantly greater than in group α2b at weeks 4, 8, and 12. In group α2a, viral decline was significantly greater in SVR patients than in non-SVR patients at week 2, whereas significantly greater viral decline in SVR patients was found during weeks 1-12 in group α2b. The first-phase viral decline rate was significantly larger in group α2a than in group α2b (1.31±0.84 vs. 0.70±0.97 log IU/mL/day; p<0.0001). Within SVR patients, first-phase viral decline rate was significantly larger in group α2a compared with group α2b (1.45±0.85 vs. 0.78±1.0 log IU/mL/day; p<0.0001). Second-phase viral decline rate was comparable between the groups. Conclusions: Peg-IFNα2a showed earlier viral decline than peg-IFNα2b and the difference was obvious, especially in the first-phase viral decline.

UR - http://www.scopus.com/inward/record.url?scp=82755168728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755168728&partnerID=8YFLogxK

U2 - 10.12659/MSM.882127

DO - 10.12659/MSM.882127

M3 - Article

C2 - 22129899

AN - SCOPUS:82755168728

VL - 17

SP - CR687-CR691

JO - Medical Science Monitor

JF - Medical Science Monitor

SN - 1234-1010

IS - 12

ER -